



**By E-Mail**

March 11, 2020

**To: The Office of the Vermont Attorney General**  
AGO.highcostprescriptiondrugs@vermont.gov

Notification of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

On March 2, 2020, the Food & Drug Administration (FDA) approved SARCLISA (isatuximab-irfc) for the treatment of certain previously treated patients with Relapsed/Refractory Multiple Myeloma (RRMM). Sanofi-aventis U.S. LLC (referred to herein as "Sanofi"), manufactures SARCLISA, which has a wholesale acquisition cost (WAC) that exceeds the threshold set for a specialty drug under the Medicare Part D program. Therefore, pursuant to 18 V.S.A. § 4637(b), Sanofi hereby provides written notice to the Office of the Attorney General that it introduced SARCLISA to the commercial market on March 9, 2020. We have provided information about the new prescription drug in the grid below.

Manufacturer	sanofi-aventis U.S. LLC
Product Name	SARCLISA (isatuximab-irfc)
NDC	NDC - 0024-0656-01 (per 500 mg / 25mL, single-dose vial)
Date of Introduction to Market	March 9, 2020

SARCLISA is also available in a lower dose (100 mg/ 5 mL, Single-dose vial) which does not meet the threshold for reporting.

In providing this notice, Sanofi expressly reserves any and all rights or claims it may have with respect to 18 V.S.A. § 4637, the company's interpretation thereof, or the statute's application to Sanofi, sanofi-aventis U.S. LLC, or any other entity affiliated with or otherwise under the control of Sanofi.

Sincerely,

A handwritten signature in black ink, appearing to read "Phillip Ridolfi", with a long horizontal flourish extending to the right.

Phillip Ridolfi

Head of Business Operations and Support, Sales Support